$NTRA

Fesko John sold $292K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,438 shares of Natera, Inc. (NTRA) at $202.84 ($0.29M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed event is an officer open-market sale under a pre-arranged 10b5-1 plan, which typically reduces the signal value versus discretionary selling.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The article provides only the sale details; it does not include any concurrent buy transactions, changes in guidance, or new company events that would justify a fundamental repricing.

Relevance 3/10Novelty 3/10Timing: Filed 2026-05-28, disclosing a sale executed 2026-05-26.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera Form 4 shows officer Fesko John sold 1,438 shares at $202.8398 on 2026-05-26 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, with no accompanying company news or guidance change.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be interpreted as diversification or liquidity needs rather than negative fundamentals, especially when tied to a 10b5-1 plan.

Key entities

  • Natera, Inc.

    Company whose Form 4 insider sale is disclosed.

  • Fesko John

    Natera officer (President, Chief Business Officer) who sold shares.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.